Examkin

Question

Difficulty: EasyHemodynamic and Coagulation Processes

Match the following commonly used antithrombotic and anticoagulant agents with their primary foundational mechanism of action in the coagulation and hemodynamic pathways.

  • Unfractionated HeparinActivates antithrombin III, accelerating the inactivation of thrombin and factor Xa
  • WarfarinInhibits vitamin K epoxide reductase, preventing the gamma-carboxylation of factors II, VII, IX, and X
  • AspirinIrreversibly inhibits cyclooxygenase-1 (COX-1), decreasing the production of thromboxane A2
  • ClopidogrelIrreversibly blocks the P2Y12 component of ADP receptors on the platelet surface

Answer

Unfractionated Heparin matches with antithrombin III activation; Warfarin matches with vitamin K epoxide reductase inhibition; Aspirin matches with COX-1 inhibition; and Clopidogrel matches with P2Y12 ADP receptor blockade.
Each agent targets a unique and foundational step in either primary hemostasis (platelet plug formation via COX-1 or P2Y12) or secondary hemostasis (coagulation cascade via antithrombin III or vitamin K reduction). Correctly matching these mechanisms is essential for foundational pharmacological knowledge.

Step-by-Step Solution

1
Analyze Unfractionated Heparin's mechanism of action.
Matches with antithrombin III activation.
Heparin is a glycosaminoglycan that relies on antithrombin III to exert its immediate anticoagulant effect on the coagulation cascade.
2
Analyze Warfarin's mechanism of action.
Matches with inhibition of vitamin K epoxide reductase.
Warfarin prevents the recycling of vitamin K, inhibiting the maturation of factors necessary for secondary hemostasis.
3
Analyze Aspirin's mechanism of action in hemostasis.
Matches with irreversible COX-1 inhibition.
Aspirin exerts its antiplatelet effect by inhibiting thromboxane A2 synthesis via COX-1 acetylation, affecting primary hemostasis.
4
Analyze Clopidogrel's mechanism of action.
Matches with P2Y12 ADP receptor blockade.
Clopidogrel is an ADP receptor antagonist that directly blocks surface receptors preventing platelet aggregation.

Key Concept

Pharmacologic mechanisms targeting the coagulation cascade and platelet activation.
Rate this question

Topics

Hemodynamic and Coagulation Processes

More questions from this topic